Not Just Chips and Giggles: Pairing High‑Flying Tech With Serious Healthcare Winners -( $AI $AMD $CAH $CVS $EPRX $MODD $JNJ $NVDA $PODD $TNDM ) by John F. Heerdink, Jr. 10 hours ago Read more Is Nanobiotix Building a Toll Road for Genetic Drugs? Early Preclinical Data Says “Maybe” -( $NBTX $JNJ $IBB $XBI ) by John F. Heerdink, Jr. 1 day ago Read more An Applied $7.5 Billion Signal From the Heartland -( $APLD $CRWV $GOOG ) by John F. Heerdink, Jr. 1 day ago Read more Precision Meets Possibility: Inside Tribe Public’s Latest CEO Event on Targeted Alpha Therapy with NAYA by John F. Heerdink, Jr. 3 days ago Read more From Waistlines to Warheads: How GLP‑1 Cash Is Quietly Fueling the Radiopharma Revolution -( $AZN $BMY $LLY ) by John F. Heerdink, Jr. 4 days ago Read more From Shopping Carts to Smart Carts: Walmart’s Digital Health Push Meets Lilly’s GLP‑1 Boom – ( $AMGN $LLY $MODD $NVO $PFE $WMT ) by John F. Heerdink, Jr. 4 days ago Read more From Shots to Patch Pumps: How Eli Lilly and Modular Medical Are Quietly Repricing Metabolic Risk -( $LLY $MODD ) by John F. Heerdink, Jr. April 17, 2026 Read more Tribe Public Shines a Spotlight on Naya Therapeutics as Next-Gen Oncology Steps Onto the Investor Stage by John F. Heerdink, Jr. April 17, 2026 Read more Hims & Hers, RFK Jr., And A Market Suddenly Bullish On Peptides (With A ‘Pivot’ In Diabetes Care) – ( $HIMS $MODD ) by John F. Heerdink, Jr. April 16, 2026 Read more Tribe Public Hosts Exclusive CEO Event: “Can Targeted Alpha Therapy Cure Cancer?” by John F. Heerdink, Jr. April 13, 2026 Read more Read more
